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Letters to the Editor
Encephalopathy, lactic acidosis, hyperammonaemia and
5-fluorouracil toxicity
Sir,
I read with interest the recent article by Yeh and Cheng (1997)
concerning toxicity of the 5-fluorouracil/leucovorin (HDFL)
treatment protocol. The clinical presentation of side-effects was
encephalopathy associated with laboratory findings of hyper-
ammonaemia, lactic acidosis and hypotriglyceridaemia. This
phenomenon was present in 5.7% of patients treated with the
HDFL protocol. The authors conclude that ammonia as the end-
product of 5FU metabolism overloads capacity of the Krebs cycle
and that under HDFL treatment a large amount offluoroacetic acid
directly inhibits the ATP-producing Krebs cycle (Yeh and Cheng,
1997). I have the following comments to make: one should distin-
guish between the Krebs-Henseleit cycle, which is ureasynthetic,
and the Krebs tricarboxylic acid cycle, which generates redox
equivalents for the electron transport chain and consequent
synthesis ofATP. Both these cellular processes require intact mito-
chondria to operate. In hepatic encephalopathy it is of interest to
assess the clinical stage ofencephalopathy using available scoring
scales (i.e. Glasgow Coma Scale). The profile of plasma amino
acids informs about the elevation of glutamine as this amino acid
is an essential part of the ammonia disposal system and is also
related to acid-base balance (Guder et al, 1987). Moreover, other
constituents ofthe ureagenic cycle are also evaluated. Alanine and
pyruvate measurements are of value for assessment of the redox
status and optimally, AKBR is suggested as the best prog-
nostic and functional test of cytoplasmic (lactate/pyruvate) and
mitochondrial (beta-hydroxybutyrate/acetacetate) redox state
(Asonuma, 1991; Saibara, 1994; Takahashi, 1997). Hypotri-
glyceridaemia is usually accompanied by elevated serum free fatty
acids and hypoglycaemia usually develops because of liver gluco-
neogenesis failure. Altogether, these findings indicate severe
disturbance of the liver function in terms of (a) impaired ureagen-
esis (elevated ammonia, elevated glutamine, decreased urea, alka-
losis); (b) impaired oxidative phosphorylation (lactate/pyruvate);
and (c) impaired synthesis of complex lipoproteins. Interpretation
of these findings is, in my opinion, consistent with hepatic
dysfunction; the authors assumed that none of their patients had
hepatic or renal dysfunction.
The frequency of this complication, which was 5.7% in the
group under study, is high and could imply a certain genetic basis.
I wish to offer the following differential diagnostic considerations
to complement those discussed by Yeh and Cheng. Dihydro-
pyrimidine dehydrogenase deficiency in its incomplete form
remains a possibility (Wei et al, 1996) as the complexity of the
compound-heterozygous status in which both alleles harbour
different functionally more or less relevant mutations (also called
polymorphisms) may trigger a complex clinical response under
stress conditions (i.e. substrate loading superimposed on disease
status). Mitochondrial disorders are another possibility (OMIM
1996). Their genetics are based on the populational rather than on
a Mendelian basis and their spectrum of clinical presentation is
extremely broad. Loss ofstructural integrity ofmitochondria leads
to disruption of the proton gradient and consequently to failure of
energy (ATP) production. In the liver, these events result in failure
of the Krebs-Henseleit ureasynthetic cycle and consequent hyper-
ammonaemia. Lactic acidosis develops because of derangement
(regardless of the nature) of the cellular redox status and
microvesicular fatty infiltration (in the liver) appears because of
inability to create and export complex lipoproteins. Again, one can
hypothesize that a stress situation superimposed on a genetically
altered background (i.e. certain proportion ofprimarily malfunc-
tioning mitochondria) may trigger a response such as this. Liver
toxicity of several pyrimidine derivatives has been previously
demonstrated for AZT (Mondica-Napolitano, 1993) and fialuri-
dine (Lewis et al, 1996) and the mechanism was related to
damaged mitochondria. The inability of mitochondria to synthe-
size thymidine de novo may be the single most important reason
for mitochondrial toxicity of pyrimidine analogues (Shaw and
Locarnini 1995). The point raised by Yeh and and Cheng is impor-
tant for two reasons: (a) assessment ofpatients with this patholog-
ical reaction to HDFL treatment should be comprehensive and in
addition should include determinations ofplasma amino acids and
pyruvate; (b) when these side-effects occur the clinician in charge
should consider consultation with a medical geneticist to review
possibilities mentioned above in the context ofthe patient's family
history. Gaining experience and knowledge could perhaps result in
delineation of a test protocol assessing thepharmacogenetic back-
ground of patients scheduled for HDFL treatment. Notably, the
importance of pharmacogenetics in cancer treatment has already
been recognized for thiopurine methyltransferases (Szumlanski et
al 1996) and dihydropynimidine dehydrogenases (Meinsma et al,
1995; Beuzeboc, et al, 1996).
D Valik
Masarvk Memorial Canicer Institute, Departmenit ofBiochemistr;
Zlutv kopec 7, 653 62 Brno, The Czech Republic
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5-Fluorouracil-related encephalopathy: at least two
distinct pathogenetic mechanisms exist - reply
Sir,
We greatly appreciate Dr Valik's comments, which have provided
new information for studying the possible pathogenetic mecha-
nisms of HDFL-related encephalopathy. However, we would like
to take this opportunity to clarify some ofthe points that we raised
in the original article (Yeh et al, 1997).
The two Krebs cycles mentioned by Dr Valik, i.e. the Krebs
tricarboxylic acid cycle (Krebs citric acid cycle) and the
Krebs-Henseleit urea cycle, correspond to the Krebs cycle and the
urea cycle in our article respectively. We considered that these two
simplified terms are well accepted by readers and are widely used
in the literature (Lehninger et al, 1993a,b; Mayes et al, 1993;
Rodwell et al, 1993). We believed that the metabolic
encephalopathy observed by us was a new pathogenetic entity,
which differed significantly from the more common hepatic
encephalopathy. Therefore, we chose not to use the traditional
clinical grading system for hepatic encephalopathy (Sherlock et al,
1954, 1989). We have indeed documented that none ofourpatients
had hepatic or renal dysfunction in terms of the conventional
biochemical criteria (Yeh et al, 1997). Also, none of them had
hypoglycaemia.
The relatively high overall incidence (5.7%) of HDFL-related
encephalopathy in our patients did not necessarily imply a genetic
basis for this condition. Instead, all our evidence has indicated that
dihydropyrimidine dehydrogenase (DPD) deficiency, even in its
incomplete form, is probably not the pathogenetic mechanism of
HDFL-related encephalopathy. 5-FU treatment in patients with
DPD deficiency should result in severe mucosal and haemato-
logical toxicities (Tuchman et al, 1985; Diasio et al, 1988), which
were definitely not observed in all our 16 patients. Also, the
encephalopathy due to DPD deficiency should characteristically
present at the first exposure to drug, and should have low or no
catabolic products (such as ammonia) of 5-FU (Tuchman et al,
1985; Diasio et al, 1988; Takimoto et al, 1996). Among our 16
patients, the encephalopathy developed at the first exposure to
HDFL in eight patients, but developed at or after the second expo-
sure in another eight patients. On rechallenge with HDFL, only
8 out of 12 patients developed recurrent encephalopathy. These
observations strongly argued that DPD deficiency is the cause of
HDFL-related encephalopathy.
We suggest that there are at least two distinct pathogenetic enti-
ties of 5-FU-related encephalopathy. The first is the 'DPD defi-
ciency type'. DPD deficiency results in failure of the first step of
5-FU catabolism and leads to 5-FU accumulation (Tuchman et al,
1985; Diasio et al, 1988; Takimoto et al, 1996). High concentration
of5-FU penetrates into cerebrospinal fluid (CSF) and causes acute
demyelination of the neurons. After discontinuation of 5-FU, it
usually takes weeks to months for remyelination to occur (Kerr et
al, 1984; Takimoto et al, 1996). High plasma level of5-FU should
also cause severe gastrointestinal (GI) and marrow toxicities
(Tuchman et al, 1985; Diasio et al, 1988; Takimoto et al, 1996).
And few or no catabolites (FUPA, 5-fluoroureidopropionic acid;
FBAL, 2-fluoro-fi-alanine; ammonia, etc.) should be detected
because ofthe failure of5-FU catabolism. The second is the '5-FU
catabolite type' (Yeh et al, 1997). The major catabolic pathway of
5-FU is intact. However, the relatively large dose
of 5-FU results in transient accumulation of 5-FU catabolites
(including ammonia). If the disposal of the latter is not adequate,
such as under conditions of malnutrition and/or impaired Krebs
cycle, transient encephalopathy ensues. No demyelinating changes
and no severe GI or marrow toxicities should be observed, and
recovery from encephalopathy usually occurs within a few days
(Yeh et al, 1997). Theoretically, a specific DPD inhibitor (such as
5-ethynyluracil) may protect the patients from the encephalopathy
ofthe 5-FU catabolite type (Davis et al, 1994).
We, however, cannot completely exclude other possible mecha-
nisms ofthe hyperammonaemia observed in our patients. The one
raised by Dr Valik, which hypothesized that a stress situation
superimposed on a genetically altered background in urea cycle
(i.e. incomplete form of urea cycle enzyme deficiencies, such as
ornithine transcarbamoylase deficiency) is certainly a possibility
that deserves further exploration (Sinatra et al, 1975; Snodgrass et
al, 1976). We also agree with Dr Valik that patients with HDFL-
related encephalopathy should have an examination of plasma
amino acids (glutamine, arginine, etc.) and the intermediates of
urea cycle (ornithine, citrulline, argininosuccinate, etc.) (Rodwell
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